Interferon-α sensitizes HBx-expressing hepatocarcinoma cells to chemotherapeutic drugs through inhibition of HBx-mediated NF-κB activation

Virology Journal

Volumn 10, Issue , 2013, Pages

  Liu, Yanning ^a   Lou, Guohua ^a   Wu, Wei ^a   Shi, Yu ^a   Zheng, Min ^a   Chen, Zhi ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

HBx; Hepatocellular carcinoma; Interferon ; MDR; NF B

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BREAST CANCER RESISTANCE PROTEIN; FLUOROURACIL; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; HEPATITIS B VIRUS X PROTEIN; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; SURVIVIN; TRANSCRIPTION FACTOR RELA;

ANIMAL EXPERIMENT; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; ENZYME INHIBITION; G2 PHASE CELL CYCLE CHECKPOINT; HEPATITIS B VIRUS; IC 50; IMMUNOFLUORESCENCE; LIVER CELL CARCINOMA; M PHASE CELL CYCLE CHECKPOINT; MALE; MOUSE; NONHUMAN; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL SURVIVAL; DISEASE MODELS, ANIMAL; DRUG RESISTANCE; HEPATITIS B VIRUS; HEPATOCYTES; HUMANS; INHIBITORY CONCENTRATION 50; INTERFERON-ALPHA; MALE; MICE; MICE, NUDE; TRANS-ACTIVATORS;

HEPATITIS B VIRUS; MUS;

EID: 84878231413     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-10-168     Document Type: Article

References (30)

1. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-EASL conference. European Association for the Study of the Liver. Bruix J, Sherman M, Llovet JM, J Hepatol 2001 35 421 430 10.1016/S0168-8278(01) 00130-1 11592607 (Pubitemid 32844200)
2. Clinical trials in primary hepatocellular carcinoma: current status and future directions. Nerenstone SR, Ihde DC, Friedman MA, Cancer Treat Rev 1988 15 1 31 3042129
3. Systemic therapy for advanced hepatocellular carcinoma: a review. Nowak AK, Chow PK, Findlay M, Eur J Cancer 2004 40 1474 1484 10.1016/j.ejca.2004.02. 027 15196530 (Pubitemid 38757734)
4. Overexpression of the MDR1 gene and P-glycoprotein in human hepatocellular carcinoma. Huang CC, Wu MC, Xu GW, J Natl Cancer Inst 1992 84 262 264 10.1093/jnci/84.4.262 1346405
5. Reversal of drug resistance of hepatocellular carcinoma cells by adenoviral delivery of anti-ABCC2 antisense constructs. Folmer Y, Schneider M, Blum HE, Hafkemeyer P, Cancer Gene Ther 2007 14 875 884 10.1038/sj.cgt.7701082 17704753 (Pubitemid 47557223)
6. Interferon-γ sensitizes hepatitis B virus-expressing hepatocarcinoma cells to 5-fluorouracil through inhibition of hepatitis B virus-mediated nuclear factor-κB activation. Chung C, Chung C, Gyoo Park S, Min Park Y, Cancer Sci 2007 98 1758 1766 10.1111/j.1349-7006.2007.00591.x 17711513 (Pubitemid 47487913)
7. HBsAg and HBx knocked into the p21 locus causes hepatocellular carcinoma in mice. Wang Y, Cui F, Lv Y, Hepatology 2004 39 318 324 10.1002/hep.20076 14767984 (Pubitemid 38222172)
8. Cooperative transformation of murine fibroblast NIH3T3 cells by hepatitis C virus core protein and hepatitis B virus X protein. Jung EY, Kang HK, Chang J, Virus Res 2003 94 79 84 10.1016/S0168-1702(03)00135-7 12902036 (Pubitemid 36930031)
9. COX-2 mediates hepatitis B virus X protein abrogation of p53-induced apoptosis. Cheng AS, Yu J, Lai PB, Chan HL, Sung JJ, Biochem Biophys Res Commun 2008 374 2 175 180 10.1016/j.bbrc.2008.06.098 18601905
10. NF-κB activation by hepatitis B virus X (HBx) protein shifts the cellular fate toward survival. Yun C, Um HR, Jin YH, Cancer Lett 2002 184 97 104 10.1016/S0304-3835(02)00187-8 12104053 (Pubitemid 34718111)
11. Hepatitis B virus X protein enhances NFkappaB activity through cooperating with VBP1. Kim SY, Kim JC, Kim JK, BMB Rep 2008 41 2 158 163 10.5483/BMBRep.2008.41.2.158 18315953
12. Missing pieces in the NF-κB puzzle. Ghosh S, Karin M, Cell 2002 109 Suppl 81 S96 11983155
13. NF-κB signaling pathways in mammalian and insect innate immunity. Silverman N, Maniatis T, Genes Dev 2001 15 2321 2342 10.1101/gad.909001 11562344 (Pubitemid 32899738)
14. NF-κB functions as a tumour promoter in inflammation-associated cancer. Pikarsky E, Porat RM, Stein I, Nature 2004 431 461 466 10.1038/nature02924 15329734 (Pubitemid 39329586)
15. Apoptosis and cancer chemotherapy. Makin G, Dive C, Trends Cell Biol 2001 11 22 S26 11684438
16. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Fulda S, Debatin KM, Oncogene 2006 25 4798 4811 10.1038/sj.onc.1209608 16892092 (Pubitemid 44187627)
17. Role of NF-κB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Arlt A, Gehrz A, Muerkoster S, Oncogene 2003 22 3243 3251 10.1038/sj.onc.1206390 12761494 (Pubitemid 36712936)
18. Nuclear factor-κB inhibitors as sensitizers to anticancer drugs. Nakanishi C, Toi M, Nat Rev Cancer 2005 5 297 309 10.1038/nrc1588 15803156 (Pubitemid 40488635)
19. Comparison of the efficacy of thymosin alpha-1 and interferon alpha in the treatment of chronic hepatitis B: a meta-analysis. Yang YF, Zhao W, Zhong YD, Antiviral Res 2008 77 136 141 10.1016/j.antiviral.2007.10.014 18078676
20. TNF combined with IFN-alpha accelerates NF-kappaB-mediated apoptosis through enhancement of Fas expression in colon cancer cells. Kimura M, Haisa M, Uetsuka H, Cell Death Differ 2003 10 6 718 728 10.1038/sj.cdd.4401219 12761580 (Pubitemid 36675733)
21. Interferon-alpha sensitizes human hepatoma cells to TRAIL-induced apoptosis through DR5 upregulation and NF-kappa B inactivation. Shigeno M, Nakao K, Ichikawa T, Oncogene 2003 22 1653 1662 10.1038/sj.onc.1206139 12642868 (Pubitemid 36408180)
22. Effects of hepatitis B virus X protein on the development of liver cancer. Zhang X, Zhang H, Ye L, J Lab Clin Med 2006 147 58 66 10.1016/j.lab.2005.10.003 16459163 (Pubitemid 43188997)
23. Hepatitis B virus X protein upregulates expression of calpain small subunit 1 via nuclear factor-kappaB/p65 in hepatoma cells. Zhang F, Wang Q, Ye L, Feng Y, Zhang X, J Med Virol 2010 82 6 920 928 10.1002/jmv.21753 20419804
24. Phosphorylation meets ubiquitination: the control of NF-kB activity. Karin M, Ben-Neriah Y, Annu Rev Immunol 2000 18 621 623 10.1146/annurev.immunol. 18.1.621 10837071 (Pubitemid 30365393)
25. Induction of Bcl-2 expression by hepatitis B virus pre-S2 mutant large surface protein resistance to 5-fluorouracil treatment in Huh-7 cells. Hung JH, Teng YN, Wang LH, Su IJ, Wang CC, Huang W, Lee KH, Lu KY, Wang LH, PLoS One 2011 6 12 28977 10.1371/journal.pone.0028977 22216150
26. The taccalonolides: microtubule stabilizers that circumvent clinically relevant taxane resistance mechanisms. Risinger AL, Jackson EM, Polin LA, Helms GL, LeBoeuf DA, Joe PA, Hopper-Borge E, Luduena RF, Kruh GD, Mooberry SL, Cancer Res 2008 68 21 8881 8888 10.1158/0008-5472.CAN-08-2037 18974132
27. Discovery of ixabepilone. Hunt JT, Mol Cancer Ther 2009 8 2 275 281 10.1158/1535-7163.MCT-08-0999 19174552
28. Long-term efficacy of interferon alpha therapy on hepatitis B viral replication in patients with chronic hepatitis B: a meta-analysis. Yang YF, Zhao W, Xia HM, Antiviral Res 2010 85 2 361 365 10.1016/j.antiviral.2009.10.023 19900483
29. Alpha/beta interferon inhibits cap-dependent translation of viral but not cellular mRNA by a PKR-independent mechanism. Tesfay MZ, Yin J, Gardner CL, J Virol 2008 82 6 2620 2630 10.1128/JVI.01784-07 18160435 (Pubitemid 351329153)
30. The N-terminus of PKR is responsible for the activation of the NF-kappaB signaling pathway by interacting with the IKK complex. Bonnet MC, Daurat C, Ottone C, Meurs EF, Cell Signal 2006 18 11 1865 1875 10.1016/j.cellsig.2006.02. 010 16600570 (Pubitemid 44485977)